Palomino Laboratories (PALX) Common Equity (2022 - 2025)
Palomino Laboratories (PALX) posted Common Equity of $8.1 million for Q4 2025, up 10.72% sequentially from $7.3 million in Q3 2025, and up 44335.15% YoY from N/an in Q4 2024.
Palomino Laboratories (PALX) Common Equity (2022 - 2025) Analysis & Trends
Palomino Laboratories has reported Common Equity for 4 years, with the latest figure at $8.1 million in Q4 2025.
- Quarterly Common Equity rose 44335.15% year-over-year to $8.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.1 million (up 44335.15% YoY) and the FY2025 annual result came in at $8.1 million, up 44335.15% from the prior year.
- Common Equity climbed to $8.1 million in Q4 2025 per PALX's latest filing, from $7.3 million in the prior quarter.
- Over five years, Common Equity peaked at $8.1 million in Q4 2025 and troughed at -$991653.0 in Q1 2025.
- A 4-year average of $1.3 million and a median of -$18306.0 in 2023 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 87763.29% in 2025, down 42008.41% in 2025.
- Over 4 years, Common Equity stood at -$27804.0 in 2022, then surged by 34.16% to -$18306.0 in 2023, then changed by 0.0% to -$18306.0 in 2024, then jumped by 44335.15% to $8.1 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $8.1 million, $7.3 million, and -$447236.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.10 Mn |
| Sep 30, 2025 | 7.31 Mn |
| Jun 30, 2025 | -447,236.00 |
| Mar 31, 2025 | -991,653.00 |
| Dec 31, 2024 | -18,306.00 |
| Sep 30, 2024 | -8,343.00 |
| Jun 30, 2024 | -2,009.00 |
| Mar 31, 2024 | -2,355.00 |
| Dec 31, 2023 | -18,306.00 |
| Sep 30, 2023 | -78,667.00 |
| Dec 31, 2022 | -27,804.00 |